Wuhan Binhui Biotech closed a $47 million Series B financing to support its R&D of oncolytic virus products. Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing from an affiliate of R-Bridge Healthcare Fund.